Zura Bio (Nasdaq: “ZURA”), a leading multi-asset clinical-stage biotechnology company headquartered in San Diego, CA, has successfully raised approximately $80M in funding. The funding round was led by prominent investors, including Deep Track Capital, Great Point Partners, Suvretta Capital, and a life sciences-focused investment fund, alongside additional new and existing investors. This significant investment will fuel Zura Bio’s initiatives to initiate Phase 2 clinical trials for ZB-106 in systemic sclerosis (SSc), followed by Phase 2 trials in hidradenitis suppurativa (HS).
Under the leadership of CEO Dr. Someit Sidhu, Zura Bio focuses on developing a diverse portfolio of therapeutic indications for its novel compounds, including tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168. The company aims to demonstrate the efficacy, safety, and dosing convenience of these compounds in immune and inflammatory disorders. With this funding, Zura Bio is poised to accelerate its clinical trials and advance its innovative pipeline.
Having approximately $120 million in cash and cash equivalents, Zura Bio is confident that it possesses ample resources to fund its planned operating expenses and capital expenditure requirements until 2026. This financial stability provides a solid foundation for the company’s ongoing research and development efforts, ensuring the continuation of its pioneering work in the field of biotechnology.
Zura Bio’s commitment to advancing therapeutic solutions for immune and inflammatory disorders exemplifies its dedication to improving patients’ lives. By leveraging its expertise and innovative compounds, the company is well-positioned to make significant strides in the clinical development of its pipeline and contribute to the advancement of healthcare.